81 terminated. 81 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 81 | Terminated 81 |
| Phase 2 | 7 | Terminated 7 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 654 | 2023-03-27 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 1061 | 2023-01-30 | 2025-12-15 |
| Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma Tezepelumab, Placebo - Asthma | Phase 3 | Terminated | AstraZeneca | 125 | 2022-08-09 | 2026-06-18 |
| AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department Azithromycin, Placebo - Asthma, Wheezing | Phase 3 | Terminated | University of Arizona | 840 | 2021-11-22 | 2026-06-23 |
| A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat REGN1908-1909, Matching Placebo - Allergic Rhinitis Due to Cat Allergy | Phase 3 | Terminated | Regeneron Pharmaceuticals | 446 | 2021-07-30 | 2024-06-11 |
| A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 4710 | 2021-07-14 | 2025-12-17 |
| A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) CHF6001 1600µg, CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 3973 | 2021-07-12 | 2026-02-02 |
| Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation Seretide, Placebo - Stem Cell Transplant Complications, Respiratory Disease | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 35 | 2021-05-21 | 2025-09-16 |
| Protective Role of Inhaled Steroids for Covid-19 Infection 2: Usual practice + SYMBICORT RAPIHALER, 1: Usual practice - Covid-19 Infection, Hospitalization in Respiratory Disease Department | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 146 | 2020-04-13 | 2021-08-03 |
| Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) Liposomal Cyclosporine A 5 mg, Liposomal Cyclosporine A 10 mg - Bronchiolitis Obliterans, Obliterative Bronchiolitis | Phase 3 | Terminated | Zambon SpA | 164 | 2020-03-12 | 2026-04-07 |
| Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy Brand Name: Flutiform K-haler - Asthma | Phase 3 | Terminated | Mundipharma Korea Ltd | 20 | 2019-11-26 | 2021-01-25 |
| Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) Benralizumab 30 mg, Matched placebo - Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis | Phase 3 | Terminated | AstraZeneca | 295 | 2019-11-25 | 2026-02-19 |
| Effect of Sublingual Fentanyl on Breathlessness in COPD Fentanyl citrate solution sublingual, Placebo oral liquid - Copd | Phase 2 / Phase 3 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 40 | 2019-07-01 | 2026-03-05 |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Itacitinib, Placebo, Methylprednisolone - Chronic Graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | Incyte Corporation | 155 | 2019-01-17 | 2025-10-20 |
| Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age Curosurf 80Mg/Ml Intratracheal Suspension, Ambient Air - Bronchiolitis, Viral | Phase 3 | Terminated | Azienda Ospedaliera Universitaria Integrata Verona | 9 | 2019-01-09 | 2021-04-15 |
| Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) Inhaled treprostinil solution - Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | United Therapeutics | 41 | 2018-12-21 | 2026-05-27 |
| Systemic Corticosteroids Avoidance Study in Severe Asthma Patients Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily - Asthma | Phase 3 | Terminated | Novartis Pharmaceuticals | 604 | 2018-12-13 | 2021-10-11 |
| A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol Test Product, Reference Product, Placebo - Asthma | Phase 3 | Terminated | Amneal Ireland Limited | 761 | 2018-12-06 | 2020-01-13 |
| A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence Concept2 inhaler, Concept2 inhaler with patient application - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Novartis Pharmaceuticals | 7 | 2018-07-11 | 2021-01-05 |
Showing 20 of 81. Sign in to see all of them.
Asthma (34) · Pulmonary Disease, Chronic Obstructive (29) · Bronchiolitis Obliterans Syndrome (11) · Bronchiolitis Obliterans (5) · Lung Diseases (5) · Pain (5) · Respiratory Tract Diseases (5) · Bronchitis, Chronic (4) · Constipation (4) · Diabetes Mellitus, Type 1 (4) · Diabetes Mellitus, Type 2 (4) · Opioid-Induced Constipation (4) · Pulmonary Eosinophilia (4) · Diabetes Mellitus (3)
Lung Diseases (76) · Respiratory Tract Diseases (76) · Bronchial Diseases (52) · Immune System Diseases (45) · Pathological Conditions, Signs and Symptoms (40) · Hypersensitivity, Immediate (34) · Hypersensitivity (33) · Respiratory Hypersensitivity (33) · Pathologic Processes (32) · Chronic Disease (31) · Disease Attributes (31) · Bronchitis (19) · Bronchiolitis (15) · Organizing Pneumonia (11)
Albuterol (5) · Azithromycin (2) · Insulin Aspart (2) · Prednisone (2) · Salmeterol Xinafoate (2) · Tiotropium Bromide (2) · benralizumab (2) · fevipiprant (2) · Anesthetics, Local (1) · Beclomethasone (1) · Betamethasone (1) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Dexamethasone (1) · Dietary Supplements (1)
Boehringer Ingelheim (7) · AstraZeneca (5) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (4) · Amphastar Pharmaceuticals, Inc. (3) · Areteia Therapeutics (3) · Assistance Publique - Hôpitaux de Paris (3) · Chiesi Farmaceutici S.p.A. (3) · Novartis Pharmaceuticals (3) · University of Minnesota (3) · Aeris Therapeutics (2) · Mannkind Corporation (2) · Novo Nordisk A/S (2) · Pari Pharma GmbH (2) · Pfizer (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2)
United States (43) · Germany (21) · France (20) · Canada (19) · United Kingdom (16) · Poland (15) · Spain (15) · Argentina (14) · Belgium (13) · Italy (13) · Israel (12) · Czechia (11) · Hungary (11) · Austria (10) · Brazil (10)
Mark Dransfield, MD (2) · Brandon S Lu, MD, MS (1) · Bruce A Johnson, MD (1) · Carlos Barcina, MD (1) · Charlie Casper, PhD (1)
PMID 39393433, PMID 17999759, PMID 21299475, PMID 24836125, PMID 25837041, PMID 27099485, PMID 27267111, PMID 27736154, PMID 29065885, PMID 29268739, PMID 29444682, PMID 29536781, PMID 29782642, PMID 30552284, PMID 31618297, PMID 31633896, PMID 31665017, PMID 32816215, PMID 33060632, PMID 33077567, PMID 33638931, PMID 33710614, PMID 34229290, PMID 34895218, PMID 35363600, PMID 35846226, PMID 36777695, PMID 36791280, PMID 38696034, PMID 38811045, PMID 42149992, PMID 42150582
2023 (4), 2015 (2), 2016 (2), 2018 (2), U10HL074424 (2), 2005 (1), 2008 (1), 2019 (1)